Snehal Patel Acquires 6,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel purchased 6,000 shares of Greenwich LifeSciences stock in a transaction that occurred on Thursday, April 21st. The stock was purchased at an average price of $16.09 per share, with a total value of $96,540.00. Following the completion of the purchase, the chief executive officer now directly owns 1,216,929 shares in the company, valued at $19,580,387.61. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Tuesday, April 19th, Snehal Patel purchased 6,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $16.74 per share, with a total value of $100,440.00.
• On Friday, February 11th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $19.80 per share, with a total value of $108,900.00.
• On Friday, February 4th, Snehal Patel bought 5,000 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $19.59 per share, with a total value of $97,950.00.

Shares of GLSI stock opened at $15.87 on Friday. Greenwich LifeSciences, Inc. has a twelve month low of $15.52 and a twelve month high of $48.96. The business has a fifty day simple moving average of $19.58 and a 200 day simple moving average of $25.79.

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in shares of Greenwich LifeSciences by 9.2% during the 4th quarter. BlackRock Inc. now owns 237,959 shares of the company’s stock worth $5,790,000 after buying an additional 20,105 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Greenwich LifeSciences by 18.4% during the 4th quarter. Geode Capital Management LLC now owns 67,420 shares of the company’s stock worth $1,640,000 after buying an additional 10,501 shares during the last quarter. State Street Corp lifted its position in shares of Greenwich LifeSciences by 9.4% during the 4th quarter. State Street Corp now owns 65,309 shares of the company’s stock worth $1,589,000 after buying an additional 5,595 shares during the last quarter. Millennium Management LLC increased its holdings in Greenwich LifeSciences by 101.4% in the 4th quarter. Millennium Management LLC now owns 30,414 shares of the company’s stock worth $740,000 after purchasing an additional 15,316 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Greenwich LifeSciences in the 4th quarter worth about $730,000. Institutional investors and hedge funds own 6.25% of the company’s stock.

Separately, Zacks Investment Research upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research report on Thursday.

Greenwich LifeSciences Company Profile (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.

Read More